EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1 RA IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)

Trial status: Authorised Change from baseline in body weight (kg) at Week 64, Change in HbA1c (%) from baseline at Week 64, Occurrence at Week 64 of: o CCI % of reduction from baseline body weight o CCI % of reduction from baseline body weight o CCI % of reduction from baseline body weight o CCI % of reduction from baseline body weight, Change from baseline at Week 64 in: o Fasting triglycerides (mg/dL) o Non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL), Change from baseline in SBP (mmHg) at Week 64, Change from baseline in Short Form 36 health survey (SF-36) physical function domain score at Week 64, Percent change from baseline in body weight at Week 84, Change from baseline in body weight (kg) at Week 84, Change in HbA1c (%) from baseline at Week 84 Percent change from baseline in body weight at Week 64

Change from baseline in body weight (kg) at Week 64, Change in HbA1c (%) from baseline at Week 64, Occurrence at Week 64 of: o CCI % of reduction from baseline body weight o CCI % of reduction from baseline body weight o CCI % of reduction from baseline body weight o CCI % of reduction from baseline body weight, Change from baseline at Week 64 in: o Fasting triglycerides (mg/dL) o Non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL), Change from baseline in SBP (mmHg) at Week 64, Change from baseline in Short Form 36 health survey (SF-36) physical function domain score at Week 64, Percent change from baseline in body weight at Week 84, Change from baseline in body weight (kg) at Week 84, Change in HbA1c (%) from baseline at Week 84

Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 919 participants